Cargando…

Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression

The glutamatergic modulator ketamine has been shown to rapidly reduce depressive symptoms in patients with treatment-resistant major depressive disorder (TRD). Although its mechanisms of action are not fully understood, changes in cortical excitation/inhibition (E/I) following ketamine administratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Fagerholm, Erik D., Leech, Robert, Williams, Steven, Zarate, Carlos A., Moran, Rosalyn J., Gilbert, Jessica R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164631/
https://www.ncbi.nlm.nih.gov/pubmed/34052834
http://dx.doi.org/10.1038/s41398-021-01442-3
_version_ 1783701159036321792
author Fagerholm, Erik D.
Leech, Robert
Williams, Steven
Zarate, Carlos A.
Moran, Rosalyn J.
Gilbert, Jessica R.
author_facet Fagerholm, Erik D.
Leech, Robert
Williams, Steven
Zarate, Carlos A.
Moran, Rosalyn J.
Gilbert, Jessica R.
author_sort Fagerholm, Erik D.
collection PubMed
description The glutamatergic modulator ketamine has been shown to rapidly reduce depressive symptoms in patients with treatment-resistant major depressive disorder (TRD). Although its mechanisms of action are not fully understood, changes in cortical excitation/inhibition (E/I) following ketamine administration are well documented in animal models and could represent a potential biomarker of treatment response. Here, we analyse neuromagnetic virtual electrode time series collected from the primary somatosensory cortex in 18 unmedicated patients with TRD and in an equal number of age-matched healthy controls during a somatosensory ‘airpuff’ stimulation task. These two groups were scanned as part of a clinical trial of ketamine efficacy under three conditions: (a) baseline; (b) 6–9 h following subanesthetic ketamine infusion; and (c) 6–9 h following placebo-saline infusion. We obtained estimates of E/I interaction strengths by using dynamic causal modelling (DCM) on the time series, thereby allowing us to pinpoint, under each scanning condition, where each subject’s dynamics lie within the Poincaré diagram—as defined in dynamical systems theory. We demonstrate that the Poincaré diagram offers classification capability for TRD patients, in that the further the patients’ coordinates were shifted (by virtue of ketamine) toward the stable (top-left) quadrant of the Poincaré diagram, the more their depressive symptoms improved. The same relationship was not observed by virtue of a placebo effect—thereby verifying the drug-specific nature of the results. We show that the shift in neural dynamics required for symptom improvement necessitates an increase in both excitatory and inhibitory coupling. We present accompanying MATLAB code made available in a public repository, thereby allowing for future studies to assess individually tailored treatments of TRD.
format Online
Article
Text
id pubmed-8164631
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81646312021-06-15 Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression Fagerholm, Erik D. Leech, Robert Williams, Steven Zarate, Carlos A. Moran, Rosalyn J. Gilbert, Jessica R. Transl Psychiatry Article The glutamatergic modulator ketamine has been shown to rapidly reduce depressive symptoms in patients with treatment-resistant major depressive disorder (TRD). Although its mechanisms of action are not fully understood, changes in cortical excitation/inhibition (E/I) following ketamine administration are well documented in animal models and could represent a potential biomarker of treatment response. Here, we analyse neuromagnetic virtual electrode time series collected from the primary somatosensory cortex in 18 unmedicated patients with TRD and in an equal number of age-matched healthy controls during a somatosensory ‘airpuff’ stimulation task. These two groups were scanned as part of a clinical trial of ketamine efficacy under three conditions: (a) baseline; (b) 6–9 h following subanesthetic ketamine infusion; and (c) 6–9 h following placebo-saline infusion. We obtained estimates of E/I interaction strengths by using dynamic causal modelling (DCM) on the time series, thereby allowing us to pinpoint, under each scanning condition, where each subject’s dynamics lie within the Poincaré diagram—as defined in dynamical systems theory. We demonstrate that the Poincaré diagram offers classification capability for TRD patients, in that the further the patients’ coordinates were shifted (by virtue of ketamine) toward the stable (top-left) quadrant of the Poincaré diagram, the more their depressive symptoms improved. The same relationship was not observed by virtue of a placebo effect—thereby verifying the drug-specific nature of the results. We show that the shift in neural dynamics required for symptom improvement necessitates an increase in both excitatory and inhibitory coupling. We present accompanying MATLAB code made available in a public repository, thereby allowing for future studies to assess individually tailored treatments of TRD. Nature Publishing Group UK 2021-05-29 /pmc/articles/PMC8164631/ /pubmed/34052834 http://dx.doi.org/10.1038/s41398-021-01442-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Fagerholm, Erik D.
Leech, Robert
Williams, Steven
Zarate, Carlos A.
Moran, Rosalyn J.
Gilbert, Jessica R.
Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression
title Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression
title_full Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression
title_fullStr Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression
title_full_unstemmed Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression
title_short Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression
title_sort fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164631/
https://www.ncbi.nlm.nih.gov/pubmed/34052834
http://dx.doi.org/10.1038/s41398-021-01442-3
work_keys_str_mv AT fagerholmerikd finetuningneuralexcitationinhibitionfortailoredketamineuseintreatmentresistantdepression
AT leechrobert finetuningneuralexcitationinhibitionfortailoredketamineuseintreatmentresistantdepression
AT williamssteven finetuningneuralexcitationinhibitionfortailoredketamineuseintreatmentresistantdepression
AT zaratecarlosa finetuningneuralexcitationinhibitionfortailoredketamineuseintreatmentresistantdepression
AT moranrosalynj finetuningneuralexcitationinhibitionfortailoredketamineuseintreatmentresistantdepression
AT gilbertjessicar finetuningneuralexcitationinhibitionfortailoredketamineuseintreatmentresistantdepression